# ZEJULA (niraparib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/niraparib

> The FDA approved ZEJULA (niraparib), sponsored by GSK plc (GSK), on April 26, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ZEJULA (niraparib) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Ovarian Neoplasms](https://sec-api.dev/indications/ovarian-neoplasms), [Neoplasms](https://sec-api.dev/indications/neoplasms) |
| Modality | small_molecule |
| FDA designations | orphan, priority review |

## Timeline

### March 27, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208447 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170327, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208447%22

### April 29, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208447 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20200429, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208447%22

### December 8, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208447 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20221208, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208447%22

### April 26, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214876 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20230426, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214876%22

### April 26, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208447 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20230426, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208447%22

### June 18, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214876 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250618, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214876%22

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03981796 (A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-26 (ESTIMATED); Lead Sponsor Tesaro, Inc.." https://clinicaltrials.gov/study/NCT03981796

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03981796 (A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-26 (ESTIMATED); Lead Sponsor Tesaro, Inc.." https://clinicaltrials.gov/study/NCT03981796

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Ovarian Neoplasms; Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04641247 (A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT04641247

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Ovarian Neoplasms; Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04641247 (A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT04641247

## Same indication

- [Mocertatug rezetecan](https://sec-api.dev/pdufa/mocertatug-rezetecan) (GSK)
- [Mocertatug rezetecan (mo-rez)](https://sec-api.dev/pdufa/mocertatug-rezetecan-mo-rez) (GSK)
- [Cyramza (ramucirumab)](https://sec-api.dev/pdufa/ramucirumab) (LLY)
- [Sofetabart mipitecan](https://sec-api.dev/pdufa/sofetabart-mipitecan) (LLY)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/niraparib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZEJULA (niraparib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/niraparib

```bibtex
@misc{secapidev_pdufa_niraparib_20261116,
  title        = {ZEJULA (niraparib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/niraparib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_niraparib_20261116","title":"ZEJULA (niraparib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/niraparib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
